Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.
about
Covariate pharmacokinetic model building in oncology and its potential clinical relevance.Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations.Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgeryChanges in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelPopulation pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.Time-dependent clearance of mycophenolic acid in renal transplant recipientsApplication of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial killPopulation pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovirUse of a linearization approximation facilitating stochastic model building.Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix ComputationsThe CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.A strategy for residual error modeling incorporating scedasticity of variance and distribution shape.Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase.Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resamplingdOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap.Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.Concordance between criteria for covariate model building.Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.An automated sampling importance resampling procedure for estimating parameter uncertainty.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.Useful pharmacodynamic endpoints in children: selection, measurement, and next steps.
P2860
Q27687599-A2148CB4-536E-4A4F-B810-86C164D59858Q31095157-1D4C3193-CDB2-4586-B59E-1B6E8A977C99Q31144236-D07151E6-8AF5-4439-A357-FD63A3576E81Q33574126-A924D331-2FCC-44BD-B286-1E945865CBE6Q35827409-8EC57C61-832E-400A-9DC0-0E52A23CD1D7Q36024478-F670F5C7-C1D0-4925-97BC-E16777AC3DD4Q36171772-FE84154F-F632-44D7-A0BC-250CFF924A3FQ37247594-740AA232-4CAE-4A48-A0ED-C291248C3D4AQ38555312-0ADB771D-CC03-4CDA-BEBE-0378987DA64BQ38790640-6098CFA1-8F91-493B-974C-67C65B88F9E2Q38986439-B8385E4F-ED40-4505-8557-E10AD224E5BAQ38996409-296C90C5-DE98-484D-9A77-0F44EE653071Q39126990-C3ACF775-6AB9-49D5-AF15-349431A21EF7Q39300554-B784DB0A-1DDE-435A-AC23-A19A0536FFB3Q39300563-E151A572-0900-435A-940B-FDE3C39C4B21Q40489239-8420F3F0-02C7-458C-8093-7A92F28DCFD8Q45343385-39DC9EE3-9F51-41A1-B8B3-11E0C2DEE884Q46027436-93EE71A3-A3EA-4547-A4C3-E590B64EA55EQ46078169-5CA07715-2BFE-4B14-9DFB-A59CDD5339B6Q46119145-F1DC80A5-69B5-4CB1-8B65-DD4E71BFF3E5Q46380705-16CF4ED7-4DE7-4A62-B3B1-D881375D8B77Q47103417-2EAE96EE-46DC-4E31-8E9F-BC6E3AF467BCQ55360869-9D2A1EB4-311B-4674-8B0C-0696A8AB9194
P2860
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Models for time-varying covari ...... etic-pharmacodynamic analysis.
@en
Models for time-varying covari ...... etic-pharmacodynamic analysis.
@nl
type
label
Models for time-varying covari ...... etic-pharmacodynamic analysis.
@en
Models for time-varying covari ...... etic-pharmacodynamic analysis.
@nl
prefLabel
Models for time-varying covari ...... etic-pharmacodynamic analysis.
@en
Models for time-varying covari ...... etic-pharmacodynamic analysis.
@nl
P2093
P2860
P1476
Models for time-varying covari ...... etic-pharmacodynamic analysis.
@en
P2093
Alison H Thomson
Mats O Karlsson
Peter A Milligan
Ulrika Wählby
P2860
P304
P356
10.1111/J.1365-2125.2004.02170.X
P407
P577
2004-10-01T00:00:00Z